Jose Tapia
@tapiajc.bsky.social
GI Medical Oncologist at Barts Cancer Institute. Clinical trials and drug development | ⚽️fan | Views my own.
🔗 https://uk.linkedin.com/in/tapiajc
🔗 https://uk.linkedin.com/in/tapiajc
Reposted by Jose Tapia
📢Calling all Renal Clinicians
Screening Brain Imaging in asymptomatic metastatic #RenalCancer is an ongoing area of debate
UK ROC is trying to get a picture of imaging practice across the UK (&beyond)!
Get involved!
4 minute survey below👇
forms.gle/RmsAWug54YxZ...
@tapiajc.bsky.social
Screening Brain Imaging in asymptomatic metastatic #RenalCancer is an ongoing area of debate
UK ROC is trying to get a picture of imaging practice across the UK (&beyond)!
Get involved!
4 minute survey below👇
forms.gle/RmsAWug54YxZ...
@tapiajc.bsky.social
CNS imaging for renal cell carcinoma
Background:
Brain metastases are a critical site of disease progression in patients with metastatic renal cell carcinoma (mRCC). They are associated with a lower median and overall survival rate. A re...
forms.gle
June 24, 2025 at 11:26 AM
📢Calling all Renal Clinicians
Screening Brain Imaging in asymptomatic metastatic #RenalCancer is an ongoing area of debate
UK ROC is trying to get a picture of imaging practice across the UK (&beyond)!
Get involved!
4 minute survey below👇
forms.gle/RmsAWug54YxZ...
@tapiajc.bsky.social
Screening Brain Imaging in asymptomatic metastatic #RenalCancer is an ongoing area of debate
UK ROC is trying to get a picture of imaging practice across the UK (&beyond)!
Get involved!
4 minute survey below👇
forms.gle/RmsAWug54YxZ...
@tapiajc.bsky.social
Reposted by Jose Tapia
🚨May is Bladder Cancer awareness month🚨
What better way to mark this than a Simply Oncology Bladder Cancer episode with the irrepressible
@alisonbirtle.bsky.social
🎙️We discuss peri-operative treatment & NIAGARA trial
#BladderCancer
@tapiajc.bsky.social @achoud72.bsky.social
@abcuk.bsky.social
What better way to mark this than a Simply Oncology Bladder Cancer episode with the irrepressible
@alisonbirtle.bsky.social
🎙️We discuss peri-operative treatment & NIAGARA trial
#BladderCancer
@tapiajc.bsky.social @achoud72.bsky.social
@abcuk.bsky.social
May 29, 2025 at 2:28 PM
🚨May is Bladder Cancer awareness month🚨
What better way to mark this than a Simply Oncology Bladder Cancer episode with the irrepressible
@alisonbirtle.bsky.social
🎙️We discuss peri-operative treatment & NIAGARA trial
#BladderCancer
@tapiajc.bsky.social @achoud72.bsky.social
@abcuk.bsky.social
What better way to mark this than a Simply Oncology Bladder Cancer episode with the irrepressible
@alisonbirtle.bsky.social
🎙️We discuss peri-operative treatment & NIAGARA trial
#BladderCancer
@tapiajc.bsky.social @achoud72.bsky.social
@abcuk.bsky.social
Powerful message from Prof Rob Jones. A must for all oncologists treating #BladderCancer in the UK, particularly for trainees. Treatment strategies are evolving and we need to remember: “treat the patient, not the service”.
☄️New
@simplyoncology.bsky.social
episode out tomorrow.
🎙️AC/DC were Back in Black but Simply Oncology is Back in Bladder ⚡️with the amazing Prof Rob Jones.
Part 1 of 2 on a free ranging overview of metastatic bladder cancer treatment in the UK
🚨
@tapiajc.bsky.social
@beatsoncharity.bsky.social
@simplyoncology.bsky.social
episode out tomorrow.
🎙️AC/DC were Back in Black but Simply Oncology is Back in Bladder ⚡️with the amazing Prof Rob Jones.
Part 1 of 2 on a free ranging overview of metastatic bladder cancer treatment in the UK
🚨
@tapiajc.bsky.social
@beatsoncharity.bsky.social
May 2, 2025 at 7:37 PM
Powerful message from Prof Rob Jones. A must for all oncologists treating #BladderCancer in the UK, particularly for trainees. Treatment strategies are evolving and we need to remember: “treat the patient, not the service”.
Grateful to be included on this list alongside such great minds as Dr @yukselurun.bsky.social Much appreciated, @Larvol 😊
I’m always inspired by the brilliant minds on this list (and many others!) who generously share insights and push the field of oncology forward.
Grateful to @larvol for the inclusion. @ascocancer.bsky.social
Grateful to @larvol for the inclusion. @ascocancer.bsky.social
April 9, 2025 at 6:46 AM
Grateful to be included on this list alongside such great minds as Dr @yukselurun.bsky.social Much appreciated, @Larvol 😊
=>2L at #O3B trial in #RCC #ASCOGU25. Would you try the new anti-CTLA4 (Quavonlimab) in anti-CTLA4-naive pts?
PEM/Q vs PEM/Len.
ORR: 30% vs 40%.
1yPFS: 39% vs 34%.
1yOS 75% vs 82%.
TRAE: 25% vs 49%
irAE: 20% vs 44% (only 5% G3+)
Treatment every 6 weeks.
@rickyfrazer1.bsky.social
PEM/Q vs PEM/Len.
ORR: 30% vs 40%.
1yPFS: 39% vs 34%.
1yOS 75% vs 82%.
TRAE: 25% vs 49%
irAE: 20% vs 44% (only 5% G3+)
Treatment every 6 weeks.
@rickyfrazer1.bsky.social
April 6, 2025 at 12:33 PM
=>2L at #O3B trial in #RCC #ASCOGU25. Would you try the new anti-CTLA4 (Quavonlimab) in anti-CTLA4-naive pts?
PEM/Q vs PEM/Len.
ORR: 30% vs 40%.
1yPFS: 39% vs 34%.
1yOS 75% vs 82%.
TRAE: 25% vs 49%
irAE: 20% vs 44% (only 5% G3+)
Treatment every 6 weeks.
@rickyfrazer1.bsky.social
PEM/Q vs PEM/Len.
ORR: 30% vs 40%.
1yPFS: 39% vs 34%.
1yOS 75% vs 82%.
TRAE: 25% vs 49%
irAE: 20% vs 44% (only 5% G3+)
Treatment every 6 weeks.
@rickyfrazer1.bsky.social
Reposted by Jose Tapia
🎙️@simplyoncology.bsky.social episode on #BladderCancer out 14/03/2025
🎙️We talk to leading bladder radiotherapy expert Professor Ananya Choudhury.
🎙️@achoud72.bsky.social discusses her views on bladder preservation and radiotherapy.
🎙️Fascinating insights from a world expert in bladder cancer 👇
🎙️We talk to leading bladder radiotherapy expert Professor Ananya Choudhury.
🎙️@achoud72.bsky.social discusses her views on bladder preservation and radiotherapy.
🎙️Fascinating insights from a world expert in bladder cancer 👇
March 13, 2025 at 5:05 PM
🎙️@simplyoncology.bsky.social episode on #BladderCancer out 14/03/2025
🎙️We talk to leading bladder radiotherapy expert Professor Ananya Choudhury.
🎙️@achoud72.bsky.social discusses her views on bladder preservation and radiotherapy.
🎙️Fascinating insights from a world expert in bladder cancer 👇
🎙️We talk to leading bladder radiotherapy expert Professor Ananya Choudhury.
🎙️@achoud72.bsky.social discusses her views on bladder preservation and radiotherapy.
🎙️Fascinating insights from a world expert in bladder cancer 👇
Reposted by Jose Tapia
Latest edition of our Trials and Tribulations now out featuring @gu-cast.bsky.social Declan Murphy on the role of urologists in trial design and conduct. open.spotify.com/episode/2SKX...
Episode 12: Involve Your Urologist! Challenges facing surgical trials featuring Professor Declan Murphy
Trials and Tribulations | Oncology Trials Podcast · Episode
open.spotify.com
January 7, 2025 at 12:54 PM
Latest edition of our Trials and Tribulations now out featuring @gu-cast.bsky.social Declan Murphy on the role of urologists in trial design and conduct. open.spotify.com/episode/2SKX...
Reposted by Jose Tapia
Out today on @simplyoncology.bsky.social
🎙️Excellent follow on to last weeks ESMO Resilience Taskforce episode.
🎙️We talk to @susanabanerjee.bsky.social about individual challenges of resilience.
🎙️Susie shares some great insights on this important and common issue
#burnout
@drjonlim.bsky.social
🎙️Excellent follow on to last weeks ESMO Resilience Taskforce episode.
🎙️We talk to @susanabanerjee.bsky.social about individual challenges of resilience.
🎙️Susie shares some great insights on this important and common issue
#burnout
@drjonlim.bsky.social
March 7, 2025 at 4:28 PM
Out today on @simplyoncology.bsky.social
🎙️Excellent follow on to last weeks ESMO Resilience Taskforce episode.
🎙️We talk to @susanabanerjee.bsky.social about individual challenges of resilience.
🎙️Susie shares some great insights on this important and common issue
#burnout
@drjonlim.bsky.social
🎙️Excellent follow on to last weeks ESMO Resilience Taskforce episode.
🎙️We talk to @susanabanerjee.bsky.social about individual challenges of resilience.
🎙️Susie shares some great insights on this important and common issue
#burnout
@drjonlim.bsky.social
Reposted by Jose Tapia
📣New episode out tomorrow on
@simplyoncology.bsky.social podcast
🎙️we discuss the Current and Future Shape of Oncology with
@tomroques.bsky.social
the vice president of
@rcradiologists.bsky.social
🎙️ Be sure to check it out.
@simplyoncology.bsky.social podcast
🎙️we discuss the Current and Future Shape of Oncology with
@tomroques.bsky.social
the vice president of
@rcradiologists.bsky.social
🎙️ Be sure to check it out.
February 20, 2025 at 3:25 PM
📣New episode out tomorrow on
@simplyoncology.bsky.social podcast
🎙️we discuss the Current and Future Shape of Oncology with
@tomroques.bsky.social
the vice president of
@rcradiologists.bsky.social
🎙️ Be sure to check it out.
@simplyoncology.bsky.social podcast
🎙️we discuss the Current and Future Shape of Oncology with
@tomroques.bsky.social
the vice president of
@rcradiologists.bsky.social
🎙️ Be sure to check it out.
Looking forward to #ASCOGU25
#Prostate: Combos w/ iPARP- and Lu- , EZH2
#Urothelial: Updates, HER-2, FGFR3, and high-risk UTUC
#Renal: Updates, UO3B, KIM-1, HIF-2 inh and MET inh
#Testicular: RPLND advanced Seminoma
#Penile: IO-chemo for advanced Ca
@rickyfrazer1.bsky.social @jmcgrane.bsky.social
#Prostate: Combos w/ iPARP- and Lu- , EZH2
#Urothelial: Updates, HER-2, FGFR3, and high-risk UTUC
#Renal: Updates, UO3B, KIM-1, HIF-2 inh and MET inh
#Testicular: RPLND advanced Seminoma
#Penile: IO-chemo for advanced Ca
@rickyfrazer1.bsky.social @jmcgrane.bsky.social
February 10, 2025 at 12:46 AM
Looking forward to #ASCOGU25
#Prostate: Combos w/ iPARP- and Lu- , EZH2
#Urothelial: Updates, HER-2, FGFR3, and high-risk UTUC
#Renal: Updates, UO3B, KIM-1, HIF-2 inh and MET inh
#Testicular: RPLND advanced Seminoma
#Penile: IO-chemo for advanced Ca
@rickyfrazer1.bsky.social @jmcgrane.bsky.social
#Prostate: Combos w/ iPARP- and Lu- , EZH2
#Urothelial: Updates, HER-2, FGFR3, and high-risk UTUC
#Renal: Updates, UO3B, KIM-1, HIF-2 inh and MET inh
#Testicular: RPLND advanced Seminoma
#Penile: IO-chemo for advanced Ca
@rickyfrazer1.bsky.social @jmcgrane.bsky.social
Great podcast, John! I finally understand what PACE A, B, C , and NODE means! 🤣 I was kind of lost in my MDT.
Out today!
🎙️New Simply Oncology Episode discussing prostate radiotherapy with Dr Alison Tree.
🎙️PACE trials
🎙️37➡️5➡️?2 fractions
🎙️avoiding hormone therapy in lower risk patients 👍
And much more!
@alison-tree.bsky.social
@prostatecanceruk.bsky.social
www.buzzsprout.com/2342317/epis...
🎙️New Simply Oncology Episode discussing prostate radiotherapy with Dr Alison Tree.
🎙️PACE trials
🎙️37➡️5➡️?2 fractions
🎙️avoiding hormone therapy in lower risk patients 👍
And much more!
@alison-tree.bsky.social
@prostatecanceruk.bsky.social
www.buzzsprout.com/2342317/epis...
February 3, 2025 at 7:59 PM
Great podcast, John! I finally understand what PACE A, B, C , and NODE means! 🤣 I was kind of lost in my MDT.
Reposted by Jose Tapia
#CREST trial with positive results for #PD-1 in HR #NMIBC!
✅The study evaluated #sasanlimab (PD-1i)+BCG vs standard #BCG (induction + maintenance) in BCG-naïve, HR NMIBC.
✅The study met its primary endpoint with significant improvement of EFS
pfizer.com/news/press-rel…
@oncodaily.bsky.social
✅The study evaluated #sasanlimab (PD-1i)+BCG vs standard #BCG (induction + maintenance) in BCG-naïve, HR NMIBC.
✅The study met its primary endpoint with significant improvement of EFS
pfizer.com/news/press-rel…
@oncodaily.bsky.social
https://pfizer.com/news/press-rel…
January 11, 2025 at 8:59 AM
#CREST trial with positive results for #PD-1 in HR #NMIBC!
✅The study evaluated #sasanlimab (PD-1i)+BCG vs standard #BCG (induction + maintenance) in BCG-naïve, HR NMIBC.
✅The study met its primary endpoint with significant improvement of EFS
pfizer.com/news/press-rel…
@oncodaily.bsky.social
✅The study evaluated #sasanlimab (PD-1i)+BCG vs standard #BCG (induction + maintenance) in BCG-naïve, HR NMIBC.
✅The study met its primary endpoint with significant improvement of EFS
pfizer.com/news/press-rel…
@oncodaily.bsky.social
Reposted by Jose Tapia
So here’s a starter pack of the UK Oncologists I’ve found so far - LMK who I have missed and I will follow and add.
November 20, 2024 at 1:02 PM
So here’s a starter pack of the UK Oncologists I’ve found so far - LMK who I have missed and I will follow and add.
Reposted by Jose Tapia
🎙️New Simply Oncology episode out today.
🎙️Ep 32: Discussing Global Oncology with Dr Susannah Stanway🌍
🎙️We look at the challenges affecting delivery of cancer care in Low and Middle Income countries.
Check it out 👇
www.buzzsprout.com/2342317/epis...
#cancer #oncology #cancerequity
🎙️Ep 32: Discussing Global Oncology with Dr Susannah Stanway🌍
🎙️We look at the challenges affecting delivery of cancer care in Low and Middle Income countries.
Check it out 👇
www.buzzsprout.com/2342317/epis...
#cancer #oncology #cancerequity
January 10, 2025 at 4:20 PM
🎙️New Simply Oncology episode out today.
🎙️Ep 32: Discussing Global Oncology with Dr Susannah Stanway🌍
🎙️We look at the challenges affecting delivery of cancer care in Low and Middle Income countries.
Check it out 👇
www.buzzsprout.com/2342317/epis...
#cancer #oncology #cancerequity
🎙️Ep 32: Discussing Global Oncology with Dr Susannah Stanway🌍
🎙️We look at the challenges affecting delivery of cancer care in Low and Middle Income countries.
Check it out 👇
www.buzzsprout.com/2342317/epis...
#cancer #oncology #cancerequity
Reposted by Jose Tapia
Belzutifan + Cabozantinib shows promising 70% ORR in treatment-naive advanced ccRCC (LITESPARK-003). #KidneyCancer #Oncology #Cancer @oncoalert.bsky.social @drchoueiri.bsky.social @kidney-cancer.bsky.social @dfcibreastonc.bsky.social
January 7, 2025 at 8:00 PM
Belzutifan + Cabozantinib shows promising 70% ORR in treatment-naive advanced ccRCC (LITESPARK-003). #KidneyCancer #Oncology #Cancer @oncoalert.bsky.social @drchoueiri.bsky.social @kidney-cancer.bsky.social @dfcibreastonc.bsky.social
Reposted by Jose Tapia
🚦First episode of 2025 Simply Oncology podcast out Friday with the ever excellent Alison Birtle🎙️
We covered ‘The Triple Question in mHSPC in the last episode 🎯
🎙️This time we cover all things metastatic castrate resistant prostate cancer🎙️
@alisonbirtle.bsky.social
@simplyoncology.bsky.social
We covered ‘The Triple Question in mHSPC in the last episode 🎯
🎙️This time we cover all things metastatic castrate resistant prostate cancer🎙️
@alisonbirtle.bsky.social
@simplyoncology.bsky.social
January 1, 2025 at 2:46 PM
🚦First episode of 2025 Simply Oncology podcast out Friday with the ever excellent Alison Birtle🎙️
We covered ‘The Triple Question in mHSPC in the last episode 🎯
🎙️This time we cover all things metastatic castrate resistant prostate cancer🎙️
@alisonbirtle.bsky.social
@simplyoncology.bsky.social
We covered ‘The Triple Question in mHSPC in the last episode 🎯
🎙️This time we cover all things metastatic castrate resistant prostate cancer🎙️
@alisonbirtle.bsky.social
@simplyoncology.bsky.social
Reposted by Jose Tapia
A must-read for anyone with an interest in NHS whistleblowers. Shocking but highly readable, culminating in a surgeon being struck off, but only after many patients harmed #medsky #prostatecancer #nhs
December 26, 2024 at 9:51 AM
A must-read for anyone with an interest in NHS whistleblowers. Shocking but highly readable, culminating in a surgeon being struck off, but only after many patients harmed #medsky #prostatecancer #nhs
Excited to be in Barcelona for the 2nd #GuardConsortium meeting on drug development and regulations for urological cancer.
Happy to discuss global disparities in drug approvals for #UrothelialCarcinoma.
Happy to discuss global disparities in drug approvals for #UrothelialCarcinoma.
December 12, 2024 at 11:41 AM
Excited to be in Barcelona for the 2nd #GuardConsortium meeting on drug development and regulations for urological cancer.
Happy to discuss global disparities in drug approvals for #UrothelialCarcinoma.
Happy to discuss global disparities in drug approvals for #UrothelialCarcinoma.
Reposted by Jose Tapia
NURE-Combo trial: Neoadjuvant nivolumab + nab-paclitaxel achieved a 32.3% pathologic CR (ypT0N0) and 70.9% major pathologic response (ypT≤1N0-x) in MIBC. 12-month EFS: 89.8%. Promising results for cisplatin-ineligible patients!
#BladderCancer #Immunotherapy #Oncology @oncoalert.bsky.social
#BladderCancer #Immunotherapy #Oncology @oncoalert.bsky.social
December 7, 2024 at 9:12 AM
NURE-Combo trial: Neoadjuvant nivolumab + nab-paclitaxel achieved a 32.3% pathologic CR (ypT0N0) and 70.9% major pathologic response (ypT≤1N0-x) in MIBC. 12-month EFS: 89.8%. Promising results for cisplatin-ineligible patients!
#BladderCancer #Immunotherapy #Oncology @oncoalert.bsky.social
#BladderCancer #Immunotherapy #Oncology @oncoalert.bsky.social
Reposted by Jose Tapia
For those in urology, this starter pack has all you need to keep things flowing in the Blue Zone!
#urology #urologylife
go.bsky.app/TSRtV3g
#urology #urologylife
go.bsky.app/TSRtV3g
November 12, 2024 at 8:33 PM
For those in urology, this starter pack has all you need to keep things flowing in the Blue Zone!
#urology #urologylife
go.bsky.app/TSRtV3g
#urology #urologylife
go.bsky.app/TSRtV3g